Services Agreement with Liquid Genomics, Inc.
In March 2018, we entered into an agreement with Liquid Genomics, Inc., or Liquid Genomics, to obtain blood-based tumor profiling services
exclusively from Liquid Genomics. Liquid Genomics is a related party of NantKwest as it is a wholly owned subsidiary of NantHealth, Inc., which is a majority owned subsidiary of NantWorks. We are obligated to pay Liquid Genomics fixed, per patient
fees. The agreement has an initial term of five years and renews automatically for successive
one-year
periods, unless terminated earlier. Since January 1, 2017, we incurred $37,000 under this agreement.
Clinical Trial Agreements with John Lee, M.D. and Leonard Sender, M.D., Inc., a Professional Medical Corporation, dba Chan
Soon-Shiong Institutes for Medicine (CSSIM)
In 2017, we entered into multiple agreements with John Lee, M.D. and Leonard Sender,
M.D., Inc., a professional medical corporation, dba Chan Soon-Shiong Institutes for Medicine (CSSIM), in El Segundo, California, to conduct various clinical trials. CSSIM is a related party as it is owned by two officers of the Company and
NantWorks provides administrative services to CSSIM. One of our officers is the principal investigator for the trials on behalf of CSSIM. Since January 1, 2017, we incurred $1.5 million under this agreement.
Sublease Agreement with Tensorcom, Inc.
In April 2017, we entered into a sublease agreement with Tensorcom, Inc. (Tensorcom) related to our San Diego, California, research and
development laboratory and office space, with an initial lease from May 1, 2017 through April 30, 2018. Our Chairman and CEO indirectly owns all of the outstanding equity of Tensorcom. The sublease agreement converts to a
month-to-month
lease after the initial lease term, not to exceed the expiration of the lease agreement between us and the third party landlord. After the initial term, the
sublease agreement can be terminated by either party by providing a thirty day written notice. The sublease includes a portion of the premises consisting of approximately 6,557 rentable square feet of space. The monthly base rent is $25,000 per
month, with an annual 3% increase. Since January 1, 2017, we received $0.3 million under this agreement.
Genomic and
Proteomic Services Agreement with NantOmics, LLC
In June 2015, we entered into an agreement with NantOmics, LLC, or NantOmics, to
obtain genomic sequencing and proteomic analysis services, as well as related data management and bioinformatics services, exclusively from NantOmics. We will have rights to use the data and results generated from NantOmics services in
connection with the performance of the particular oncology trial with respect to which the services were performed, but NantOmics will own the data and results, as well as any other intellectual property it creates in performing these services for
us. We are obligated to pay NantOmics a fixed, per sample fee, determined based on the type of services being provided. The agreement has an initial term of five years and renews automatically for successive one year periods, unless terminated by us
or NantOmics. We and NantOmics have the right to terminate the agreement for convenience on 90 days prior written notice, or in the event there is a material, uncured breach of the agreement by the other party. Since January 1, 2017, we
incurred $0.2 million under this agreement.
Agreement with NanoCav, LLC
In June 2015, we entered into an agreement with NanoCav, LLC, or NanoCav, pursuant to which we obtained access to NanoCavs virus-free
cell transfection technologies on a
non-exclusive
basis. Under the agreement, NanoCav will conduct certain, mutually-agreed feasibility studies, on a fee for service basis, to evaluate the use of its cell
transfection technologies with our aNK cells. We may elect to obtain NanoCavs cell transfection equipment, and rights to its associated protocols and other intellectual property, for use only for
pre-clinical
research, or also for use in clinical and commercial applications. If we choose to qualify the
-32-